Search - tctmd.com

Displaying 561 - 580 of 692

Sort: Relevancy | Date

News Daily News

The Ups and Downs of Statin Adherence Around Acute MI Hospitalization

Todd Neale

May 25, 2016

News Conference News SCAI 2016

Gender and TAVR: Studies Highlight Different Outcomes Between Men and Women

L.A. McKeown

May 11, 2016

News Daily News

Statins Tied to Lower Mortality, Amputation Risks in PAD

Michael O'Riordan

May 09, 2016

News Daily News

STICS: No Benefit to Perioperative Statin Therapy in Cardiac Surgery, but Acute Kidney Injury Risk Increased

Michael O'Riordan

May 05, 2016

News Daily News

No More Niacin, Fibrate Combinations With Statins: FDA

Michael O'Riordan

April 19, 2016

News Daily News

USPSTF 收紧一级预防的建议，称阿司匹林应只在高危人群中使用

Michael O'Riordan

April 12, 2016

News Daily News

USPSTF Tightens Up Primary-Prevention Recommendations, Saying Aspirin Should Be Used Only in High-Risk Individuals

Michael O'Riordan

April 12, 2016

News Conference News ACC 2016

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

Michael O'Riordan

April 03, 2016

News Conference News ACC 2016

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

Michael O'Riordan

April 02, 2016

News Daily News

ACC 更新降低低密度脂蛋白胆固醇降低的建议，为依折麦布和 PCSK9 抑制剂留出了空间

Michael O'Riordan

April 02, 2016

News Daily News

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

Michael O'Riordan

April 02, 2016

News Daily News

ACC actualiza las recomendaciones para bajar el colesterol LBD, abriendo un espacio para el uso de Ezetimibe y de los inhibidores de PCSK9

Michael O'Riordan

April 02, 2016

News Industry News

Aralez Announces FDA Acceptance of New Drug Application for YOSPRALA™

March 28, 2016

News Daily News

Un Nuevo Análisis del COGENT Avala el Uso de PPI en Pacientes con Dosis Bajas de Aspirina

Caitlin E. Cox

March 23, 2016

News Industry News

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

March 01, 2016

News Daily News

‘Smoker’s Paradox’ Eliminated With Double Dose of Clopidogrel: GRAVITAS Analysis

Michael O'Riordan

February 28, 2016

News Daily News

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Shelley Wood

February 16, 2016

News Daily News

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

Michael O'Riordan

February 15, 2016

News Daily News

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD Patients

Caitlin E. Cox

February 08, 2016

News Daily News

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Michael O'Riordan

January 26, 2016

Advertisement

The Ups and Downs of Statin Adherence Around Acute MI Hospitalization

Gender and TAVR: Studies Highlight Different Outcomes Between Men and Women

Statins Tied to Lower Mortality, Amputation Risks in PAD

STICS: No Benefit to Perioperative Statin Therapy in Cardiac Surgery, but Acute Kidney Injury Risk Increased

No More Niacin, Fibrate Combinations With Statins: FDA

USPSTF 收紧一级预防的建议，称阿司匹林应只在高危人群中使用

USPSTF Tightens Up Primary-Prevention Recommendations, Saying Aspirin Should Be Used Only in High-Risk Individuals

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

ACC 更新降低低密度脂蛋白胆固醇降低的建议，为依折麦布和 PCSK9 抑制剂留出了空间

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

ACC actualiza las recomendaciones para bajar el colesterol LBD, abriendo un espacio para el uso de Ezetimibe y de los inhibidores de PCSK9

Aralez Announces FDA Acceptance of New Drug Application for YOSPRALA™

Un Nuevo Análisis del COGENT Avala el Uso de PPI en Pacientes con Dosis Bajas de Aspirina

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

‘Smoker’s Paradox’ Eliminated With Double Dose of Clopidogrel: GRAVITAS Analysis

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD Patients

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content